MedPlus Health Services Limited’s subsidiary, Optival Health Solutions Private Limited, has encountered a regulatory setback with the suspension of a drug licence for one of its stores in Karnataka. The suspension is expected to result in a potential revenue loss of ₹2.88 lakh.
The suspension, issued by the Assistant Director of Drugs Control Administration, Bangalore South Circle, pertains to a store located at the Bidadi Bus Stand in Karnataka. The order was received on 14 March 2026 and mandates a two-day suspension of the drug licence. The action was taken under Rule 65 of the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945, indicating a violation or contravention of the regulations.
The impact of this suspension, quantified in monetary terms, underscores the importance of regulatory compliance for MedPlus Health Services and its subsidiaries. The company has made the details of the suspension available on its website and the websites of the BSE and NSE for public record.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).
This article is written by Business Desk and reviewed by Aman Shukla before publication.
Comments are closed.